FATE THERAPEUTICS INC(FATE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,919 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
FATE Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for FATE THERAPEUTICS INC (FATE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FATE at 9.2/100 on a 32-signal composite quality model, placing it at rank #2,919 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (1.4) and revenue scale (1.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), FATE THERAPEUTICS INC reports quarterly revenue of $2.1M, net income of $-30.2M, free cash flow of $-23.5M. Top institutional holders of FATE by reported 13-F value include Redmile Group, BlackRock, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. FATE trades on the Nasdaq exchange and files with the SEC under CIK 1434316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FATE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FATE THERAPEUTICS INC directly from SEC EDGAR. FATE THERAPEUTICS INC's 13F Pro composite quality score has ranged between 4 and 33 since 2021, currently 9.2 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$2.1M
Net Income
Q2 2026
$-30.2M
Free Cash Flow
Q2 2026
$-23.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-51.2% YoYNet Income
+26.8% YoYOperating Income
+29.8% YoYEPS (Diluted)
+29.9% YoYTotal Assets
-27.6% YoYOp. Cash Flow
+13.7% YoYFree Cash Flow
+9.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.6M -51.2% | $13.6M -78.5% | $63.5M -34.0% | $96.3M +72.4% | $55.8M +77.7% | $31.4M |
| Net Income | $-136.3M +26.8% | $-186.3M -15.7% | $-160.9M +42.9% | $-281.7M -32.8% | $-212.2M -22.4% | $-173.4M |
| Operating Income | $-147.7M +29.8% | $-210.3M -10.4% | $-190.5M +38.2% | $-308.4M -42.1% | $-217.0M -69.4% | $-128.1M |
| EPS (Diluted) | $-1.15 +29.9% | $-1.64 +0.0% | $-1.64 +43.6% | $-2.91 -29.9% | $-2.24 -6.7% | $-2.10 |
| Total Assets | $318.9M -27.6% | $440.7M -12.9% | $506.2M -28.3% | $705.6M -23.4% | $921.5M +48.0% | $622.5M |
| Operating Cash Flow | $-106.1M +13.7% | $-122.9M +7.1% | $-132.3M +46.7% | $-248.2M -52.4% | $-162.9M -315.2% | $-39.2M |
| Free Cash Flow | $-112.0M +9.4% | $-123.6M +10.7% | $-138.4M +51.2% | $-283.8M -32.9% | $-213.6M -383.6% | $-44.2M |
Get alerted when FATE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for FATE THERAPEUTICS INC including:
Top Institutional Holders of FATE
Redmile Group, LLC
$34.8M12,872,946 shBlackRock, Inc.
$19.7M7,298,895 shVANGUARD PORTFOLIO MANAGEMENT LLC
$12.3M4,545,893 shVANGUARD CAPITAL MANAGEMENT LLC
$12.0M4,445,536 shACADIAN ASSET MANAGEMENT LLC
$11.7M4,351,250 shAQR CAPITAL MANAGEMENT LLC
$10.4M3,837,229 shTWO SIGMA INVESTMENTS, LP
$9.7M3,589,863 shJOHNSON & JOHNSON
$9.1M3,379,064 shRENAISSANCE TECHNOLOGIES LLC
$8.1M2,983,268 shMILLENNIUM MANAGEMENT LLC
$6.6M2,433,978 sh
| Fund | Value | Shares |
|---|---|---|
| Redmile Group, LLC | $34.8M | 12,872,946 |
| BlackRock, Inc. | $19.7M | 7,298,895 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.3M | 4,545,893 |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.0M | 4,445,536 |
| ACADIAN ASSET MANAGEMENT LLC | $11.7M | 4,351,250 |
| AQR CAPITAL MANAGEMENT LLC | $10.4M | 3,837,229 |
| TWO SIGMA INVESTMENTS, LP | $9.7M | 3,589,863 |
| JOHNSON & JOHNSON | $9.1M | 3,379,064 |
| RENAISSANCE TECHNOLOGIES LLC | $8.1M | 2,983,268 |
| MILLENNIUM MANAGEMENT LLC | $6.6M | 2,433,978 |
Companies Similar to FATE
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Xencor Inc
Stoke Therapeutics, Inc.
ADC Therapeutics SA
Gossamer Bio, Inc.
Arcturus Therapeutics Holdings Inc.
Lyell Immunopharma, Inc.
Nurix Therapeutics, Inc.
Voyager Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put FATE on your watchlist
Track score changes the day FATE THERAPEUTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FATE a good stock to buy?
13F Pro's AI-powered analysis of FATE THERAPEUTICS INC (FATE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FATE are available on the FATE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FATE is classified as a small company.
Which hedge funds own FATE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FATE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FATE THERAPEUTICS INC's investment landscape.